INO Earnings Prediction
The chart below shows how INO performed 10 days before and after its earnings report, based on data from the past quarters. Typically, INO sees a +7.78% change in stock price 10 days leading up to the earnings, and a -7.15% change 10 days following the report. On the earnings day itself, the stock moves by -1.40%. This data can give you a slight idea of what to expect for the next quarter's release.
INO Key Earning Data
INO Earnings Analysis
Positive
Transformation to Commercial Stage: Significant progress made in 2024 towards transforming Inovio into a commercial stage company.
Manufacturing Issue Resolution: Resolved manufacturing issues for INO-3107, allowing for the next steps in FDA submission process.
BLA Submission Timeline: Plan to submit BLA for INO-3107 through FDA's rolling submission process, with expectations for completion in the second half of 2025.
Patient Treatment Success: Clinical data shows continued improvement in patients treated with INO-3107, with 50% achieving complete response in year two.
Surgery Frequency Reduction: Mean number of surgeries required by patients decreased significantly, from 4.1 surgeries per year to 0.9 surgeries by year two.
Efficacy of INO-3107: Immunology data published supports the efficacy of INO-3107, demonstrating an anti-viral immune response.
DNA Medicines Advancement: Next generation DNA medicines technology (DMAbs) shows promise with interim results indicating durable antibody production in humans.
Commercial Strategy Development: Commercial preparations for INO-3107 are underway, including distribution strategy and pricing.
Reduced Operational Expenses: Operational expenses decreased significantly, indicating improved financial management and efficiency.
Negative
Q4 Financial Struggles: Net loss for Q4 2024 was $19.4 million, indicating ongoing financial struggles.
Annual Net Loss Analysis: Total net loss for the full year 2024 was $107.3 million, reflecting significant operational costs.
Declining Cash Reserves: Cash reserves decreased from $145.3 million at the end of 2023 to $94.1 million by the end of Q4 2024, raising concerns about financial stability.
High Operational Expenses: Operational expenses dropped to $20.5 million in Q4 2024, but this is still a high figure compared to revenue, indicating inefficiencies.
Cash Runway Concerns: Projected cash runway only extends into Q1 2026, which may limit future operational capabilities without additional funding.
High Cash Burn Concern: The company has a high operational net cash burn estimate of approximately $27 million for Q1 2025, which is concerning for sustainability.
INO FAQs
How does INO typically perform around its earnings report dates?
INO's stock performance around earnings reports can vary, but historical data shows specific patterns, such as a +7.78% change leading up to the report and a -7.15% change in the 10 days following the release.
Is Inovio Pharmaceuticals Inc (INO) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
INO Earning Call Sentiment
Inovio Pharmaceuticals, Inc. (INO) Q4 2024 Earnings Call Transcript
INO.O
2.3%
